GENE ONLINE|News &
Opinion
Blog

2020-03-24| COVID-19

Gilead’s Remdesivir Wins FDA’s Orphan Drug Designation for COVID-19 Treatment

by Ruchi Jhonsa
Share To

By Ruchi Jhonsa, Ph.D.

While the clinical trials of this promising drug against SARS-CoV-2 are still on, the FDA has provided a significant advantage to Gilead’s remdesivir today. In an announcement made this evening by the U.S. Food and Drug Administration, the agency has granted orphan drug designation to this promising experimental antiviral, a drug touted by the Trump government for COVID-19 treatment. This designation will grant Gilead Sciences, tax incentives as well as seven years of market exclusivity for drug production.

Remdesivir was already provided to patients with a severe infection on a compassionate use basis but ‘overwhelming demand’ in the past weeks forced the company to temporarily suspend drug access. This was after the news circulated about the recovery of the first coronavirus patient who happened to be under remdesivir treatment. Solid evidence from clinical trials in the coming months will tell us whether remdesivir could actually live up to its hype.

References
  1. https://www.reuters.com/article/us-health-coronavirus-gilead-sciences/gileads-potential-coronavirus-treatment-gets-fdas-orphan-drug-label-idUSKBN21A3PR
  2. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=739020
  3. https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-access-to-remdesivir-outside-of-clinical-trials

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Hemgenix Marks Most Expensive Treatment Ever and First Gene Therapy for Hemophilia B
2022-11-22
Provention’s Tzield Snags FDA’s Approval to Slow Type 1 Diabetes Progression
2022-11-20
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!